Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › RNF41 as a biomarker predicting response to lenalidomide in non-del(5q) MDS

RNF41 as a biomarker predicting response to lenalidomide in non-del(5q) MDS

US Patent 10612097 · Granted Apr 7, 2020

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Small molecule pyrin-domain targeted NLRP3 inflammasome inhibitors2025
Stapled H2 pyrin peptides2024
TLR9 ligand trap2024
Soluble CD33 for treating myelodysplastic syndromes (MDS)2023
Pathways for treating patients2022
TLR9-binding chimeric antigen receptors2022
PD1 and PDL-1 expression during progression from myelodysplastic syndrome to acu2022
Inflammasome activation in myelodysplastic syndromes2022
TLR9 targeted therapeutics2021
S100A9 levels for predicting lenalidomide and erythropoietin responsiveness2020
Inflammasome activation in myelodysplastic syndromes2020
Targeted sensitization of non-del(5q) malignant cells2020